Patrick Merle

Patrick Merle

Auto-generated profile, based on publicly available information

Patrick Merle

Service de Pneumologie et oncologie thoracique, CHU G Montpied, Clermont-Ferrand, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
JPJean-Louis Pujol
Jean-Louis Pujol
LGLaurent Greillier
Laurent Greillier
CAClarisse Audigier-Valette
Clarisse Audigier-Valette
DMDenis Moro-Sibilot
Denis Moro-Sibilot
LULionel Uwer
Lionel Uwer
PSPierre-Jean Souquet
Pierre-Jean Souquet

22 October 2015 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
CTClaire Tissot
Claire Tissot
ATAnne-Claire Toffart
Anne-Claire Toffart
SVStéphanie Villar
Stéphanie Villar
PSPierre-Jean Souquet
Pierre-Jean Souquet
PMPatrick Merle
Patrick Merle
SCSébastien Couraud
Sébastien Couraud
Plasma circulating cell-free (cf)DNA is of interest in oncology because it has been shown to contain tumour DNA and may thus be used as liquid biopsy. In nonsmall cell lung cancer (NSCLC), cfDNA quantification has been proposed for the monitoring and follow-up of patients. However, available studies are limited and need to be confirmed by studies with larger sample sizes and including patients who receive more homogenous treatments. Our objective was to assess the predictive and prognostic value of plasma cfDNA concentration in a large series of patients with NSCLC and treated with a standard chemotherapy regimen.We included samples from lung cancer patients recruited into the Pharmacogenoscan study. The cfDNA of 218 patients was extracted and quantified by fluorometry before and after two or three cycles of platinum-based chemotherapy. The association between baseline and post-chemotherapy concentrations and treatment response, assessed by RECIST (response evaluation criteria in solid tumours) or patient survival was analysed.Patients with high cfDNA concentrations (highest tertile) at baseline had a significantly worse disease-free and overall survival than those with lower concentrations (lowest and middle tertiles) (median overall survival 10 months (95% CI 10.7–13.9)versus14.2 months (95% CI 12.6–15.8), respectively; p=0.001). In multivariate analysis, increased baseline concentration of cfDNA was an independent prognostic factor. However, we did not find any association between cfDNA concentration and response to treatment.cfDNA may be a biomarker for the assessment of prognosis in NSCLC. However, total concentration of cfDNA does not appear to predict chemotherapy response.

20 April 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MWMarie Wislez
Marie Wislez
FBFabrice Barlesi
Fabrice Barlesi
BBBenjamin Besse
Benjamin Besse
JMJulien Mazieres
Julien Mazieres
PMPatrick Merle
Patrick Merle
JSJean-Charles Soria
Jean-Charles Soria
Purpose: Surgical resection plus adjuvant platinum-based chemotherapy is considered standard care for stage II to III non–small-cell lung cancer (NSCLC), but its efficacy is limited, and it involves toxic risks, justifying patient-tailored treatment. Excision repair cross-complementation group 1 (ERCC1) was shown to predict cisplatin-based chemotherapy response; EGFR mutations were predictive of epidermal growth factor receptor inhibition response.Patients and Methods: This prospective randomized phase II trial enrolled 150 patients with completely resected non–squamous cell stage II or IIIA (non-N2) tumors. Patients in the control arm (n = 74) were treated with four standard-dose courses of cisplatin plus pemetrexed (CP). In the customized treatment arm (n = 76), patients with activated EGFR mutations received erlotinib 150 mg for 1 year; ERCC1-negative patients received four CP courses, whereas ERCC1-positive patients underwent follow-up. The trial sought to demonstrate the feasibility of customized adjuvant chemotherapy based on timely biomarker analysis within a 2-month postsurgery delay. Secondary objectives were tolerability, compliance with adjuvant therapy, and biomarker distribution.Results: In arm A, all patients received CP; in arm B, seven received erlotinib, 53 were administered CP, and 16 underwent follow-up. Median erlotinib exposure was 344 days. Of the 127 patients allocated to CP, 82% received four cycles with good tolerability. The overall success rate of the trial (ie, percentage of patients with complete biomarker status able to start adjuvant treatment within 2 months of surgery) was 80%.Conclusion: The primary end point of the trial was met, demonstrating the feasibility of a national biology-driven trial in the adjuvant NSCLC setting. Nevertheless, the phase III part was canceled because of the unreliability of the ERCC1 immunohistochemical readouts.

20 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
JGJessica Garcia
Jessica Garcia
JFJulien Forestier
Julien Forestier
EDEric Dusserre
Eric Dusserre
AWAnne-Sophie WOZNY
Anne-Sophie WOZNY
FGFlorence Geiguer
Florence Geiguer
LPLéa Payen
Léa Payen
Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy) Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy)

27 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GHGuillaume Herbreteau
Guillaume Herbreteau
ALAlexandra Langlais
Alexandra Langlais
LGLaurent Greillier
Laurent Greillier
CAClarisse Audigier-Valette
Clarisse Audigier-Valette
LULionel Uwer
Lionel Uwer
JPJean-Louis Pujol
Jean-Louis Pujol
Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), prospectively collected at treatment initiation, was associated with the prognosis of SCLC, and whether it identified patients who benefited from atezolizumab. Methods: 68 patients were included in this study: 46 patients were treated with atezolizumab and 22 with conventional chemotherapy. Circulating DNA was extracted from plasma and NGS (Next Generation Sequencing) looked for mutations in the TP53, RB1, NOTCH1, NOTCH2, and NOTCH3 genes. ctDNA was detectable when at least one somatic mutation was identified, and its relative abundance was quantified by the variant allele fraction (VAF) of the most represented mutation. Results: We found that 49/68 patients (70.6%) had detectable baseline ctDNA. The most frequently identified mutations were TP53 (32/49; 65.3%) and RB1 (25/49; 51.0%). Patients with detectable ctDNA had a significantly lower disease control rate at week 6 compared with patients with no detectable ctDNA, regardless of the nature of the treatment. Detection of ctDNA was associated with a poor OS prognosis. The detection of ctDNA at a relative abundance greater than the median value was significantly associated with poor overall survival (OS) and progression free survival (PFS). Interestingly, the benefit in overall survival (OS) associated with low ctDNA was more pronounced in patients treated with atezolizumab than in patients receiving chemotherapy. Among patients whose relative ctDNA abundance was below the median, those treated with atezolizumab tended to have higher OS than those in the chemotherapy arm. Conclusion: ctDNA is strongly associated with the prognosis of SCLC patients treated with second-line immunotherapy. Its analysis seems justified for future SCLC clinical trials.

1 October 2011 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
PMPatrick Merle
Patrick Merle
BEBertrand Evrard
Bertrand Evrard
APAnne Petitjean
Anne Petitjean
JLJean-Marie Lehn
Jean-Marie Lehn
MTMarie-Paule Teulade-Fichou
Marie-Paule Teulade-Fichou
ATAndreï Tchirkov
Andreï Tchirkov
The aim of this study was to test in vitro the efficacy of TAC, an original G-quadruplex ligand, as a potential radiosensitizing agent for glioblastoma multiforme (GBM). Two human radioresistant telomerase-positive GBM cell lines (SF763 and SF767) were analyzed, with and without TAC treatment, for telomere length, cell proliferation, apoptosis, cell-cycle distribution, gene expression, cytogenetic aberrations, clonogenic survival assay, 53BP1 immunofluorescence staining, and γH2AX phosphorylation. We found that low concentrations of TAC (0.5 and 1 μmol/L) inhibited the proliferation of GBM cells in a concentration-dependent manner after only 1 week of treatment, with minimal effects on cell cycle and apoptosis. TAC treatment had no visible effect on average telomere length but modified expression levels of telomere-related genes (hTERT, TRF1, and TRF2) and induced concentration-dependent DNA damage response and dicentric chromosomes. Survival curves analysis showed that exposure to nontoxic, subapoptotic concentrations of TAC enhanced radiation-induced killing of GBM cells. Analysis of DNA repair after irradiation revealed delayed repair kinetics in GBM cells treated with TAC. Furthermore, the combined treatment (TAC and radiation) significantly increased the frequency of chromosomal aberrations as compared with radiation alone. These findings provide the first evidence that exposure to a G4 ligand radiosensitizes human glioblastoma cells and suggest the prospect of future therapeutic applications. Mol Cancer Ther; 10(10); 1784–95. ©2011 AACR.